Latest News

Dermatologists share vitiligo breakthrough news with patients


 

For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical treatment.

In July, a cream formulation of ruxolitinib (Opzelura), a Janus kinase (JAK) inhibitor, became the first repigmentation treatment approved by the FDA for nonsegmental vitiligo, the most common form of the disease.

Topical ruxolitinib was first approved in September 2021 for atopic dermatitis, and dermatologists are already writing prescriptions for its new vitiligo indication.

Dr. Seemal R. Desai, founder and medical director of Innovative Dermatology in Dallas

Dr. Seemal R. Desai

“The FDA approval of ruxolitinib for repigmentation of vitiligo is historic and groundbreaking,” Seemal R. Desai, MD, a dermatologist at the University of Texas Southwestern Medical Center, Dallas, told this news organization.

The news brings hope to patients 12 years and older who suffer from the psychosocial effects of the disease, which is estimated to affect 1.9 million to 2.8 million adults in the United States.

The announcement followed FDA approval a month earlier of another dermatologic milestone – an oral JAK inhibitor, baricitinib, which became the first treatment for patients with alopecia areata.

For Dr. Desai, the ruxolitinib news is personal. His brother, also a physician, has lived a lifetime with vitiligo. His family experience, Dr. Desai said, showed him “what a disease like this can do to a person psychologically.”

Dr. Desai said his early exposure helped lead to his own decision to dedicate his career to pigmentary diseases.

His brother won’t personally benefit from the cream because his skin has been completely depigmented and repigmentation is not of interest to him, Dr. Desai said. But both brothers are excited as physicians. “It’s really quite an emotional moment,” he said.

Getting the news to patients

As dermatologists introduce the topical treatment to patients, common questions center on why this cream is different and whether it is safe.

David Rosmarin, MD, vice chair of research and education, department of dermatology, Tufts Medical Center, Boston, led the Topical Ruxolitinib Evaluation in Vitiligo Study 1 and 2 (TruE-V1, TruE-V2), conducted in North America and Europe.

David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, Boston

Dr. David Rosmarin

He summarized some key findings.

“If patients have involvement on the face, trunk, or extremities, the data show that about half the patients at 52 weeks will get half or more of their pigment back,” he said in an interview. Results for the face alone are even better. “Half the patients will get 75% or more pigment back in the face,” Dr. Rosmarin said.

In addition, analysis of subgroups shows benefit for all patients. “Patients seem to respond similarly well across all subgroups – across gender, sex, age, ethnicity, and race,” Dr. Rosmarin said.

However, anatomic region matters, he pointed out. Skin of the head and neck responds the best, followed by skin of the trunk and extremities. The hands and feet are the most difficult to repigment because there are few hair follicles, which help enable repigmentation.

He added that it’s important to understand patients’ goals, and dermatologists shouldn’t assume that all who have vitiligo will want to undergo repigmentation. They may be interested in the new treatment but may not want it for themselves, he explained.

Pages

Recommended Reading

Synthetic, botanical agents emerging as promising melasma treatments
MDedge Dermatology
PIH in patients with dark skin responds to laser treatment: Small case series
MDedge Dermatology
Pending further study, caution recommended in treating vitiligo patients with lasers, IPL
MDedge Dermatology
Going Beyond Hydroquinone: Alternative Skin Lightening Agents
MDedge Dermatology
Deployed Airbag Causes Bullous Reaction Following a Motor Vehicle Accident
MDedge Dermatology
FDA cautions against using OTC products to remove skin spots, moles
MDedge Dermatology
Assessing Treatment Delays for Vitiligo Patients: A Retrospective Chart Review
MDedge Dermatology
Ruxolitinib found to benefit adolescents with vitiligo up to one year
MDedge Dermatology
FDA approves topical ruxolitinib for nonsegmental vitiligo
MDedge Dermatology
Pigmented Papules on the Face, Neck, and Chest
MDedge Dermatology